These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 10817552

  • 1. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
    Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D.
    Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
    [Abstract] [Full Text] [Related]

  • 2. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE.
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [Abstract] [Full Text] [Related]

  • 3. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G.
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [Abstract] [Full Text] [Related]

  • 4. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [Abstract] [Full Text] [Related]

  • 5. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P.
    Arthritis Rheum; 1998 Dec; 41(12):2196-204. PubMed ID: 9870876
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods.
    Genant HK.
    Semin Arthritis Rheum; 2001 Apr; 30(5 Suppl 2):26-32. PubMed ID: 11357169
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators.
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [Abstract] [Full Text] [Related]

  • 8. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 9. Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment.
    Watt I, Cobby M.
    Semin Arthritis Rheum; 2001 Apr; 30(5 Suppl 2):21-5. PubMed ID: 11357168
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
    Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D.
    Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [Abstract] [Full Text] [Related]

  • 12. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A, Kotulska A, Giebel S, Cader SA, Kucharz EJ.
    Przegl Lek; 2002 Dec; 59(11):916-8. PubMed ID: 12715722
    [Abstract] [Full Text] [Related]

  • 13. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 14. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J, 990757 Study Group.
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 16. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis.
    Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW.
    Genes Immun; 2005 Sep; 6(6):467-71. PubMed ID: 15931231
    [Abstract] [Full Text] [Related]

  • 17. [IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy].
    Fiocco U, Vezzù M, Cozzi L, Todesco S.
    Reumatismo; 2004 Sep; 56(1 Suppl 1):62-73. PubMed ID: 15201942
    [Abstract] [Full Text] [Related]

  • 18. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD.
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [Abstract] [Full Text] [Related]

  • 19. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 20. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.
    Bresnihan B.
    Semin Arthritis Rheum; 2001 Apr; 30(5 Suppl 2):17-20. PubMed ID: 11357167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.